

NYMOX PHARMACEUTICAL CORP

Form SC 13D

August 27, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D

Under the Securities Exchange Act of 1934 (Amendment No. __)

Nymox Pharmaceutical Corporation
(Name of Issuer)Common Shares
(Title of Class of*
Securities)67076P102
(CUSIP Number)James G. Robinson; 10 E. Lee Street,*
Suite 2705 Baltimore, MD 21202; 410-752-1414
(Name, Address and Telephone Number*
of Person Authorized to Receive Notices and Communications)
05/18/2015
(Date of*

Event which Requires Filing of this Statement)
If the filing person has*

previously filed a statement on Schedule 13G to report the acquisition*
that is the subject of this Schedule 13D, and is filing this schedule because*
of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box[].*
Note: Schedules filed in paper format shall include a signed original and five*
copies of the schedule, including all exhibits. See 240.13d-7(b) for other*
parties to whom copies are to be sent.

The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,*
and for any subsequent amendment containing information which would alter*
disclosures provided in a prior cover page. The information required on the*
remainder of this cover page shall not be deemed to be "filed" for the purpose*
of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise*
subject to the liabilities of that section of the Act but shall be subject*
to all other provisions of the Act (however, see the Notes).*

SCHEDULE 13D*
CUSIP No.
67076P1021*

NAMES OF REPORTING PERSONS*

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)*

James G. Robinson*

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) []*

(b) []

*

3

SEC USE ONLY*

4

SOURCE OF FUNDS (See Instructions)

PF*

5

Edgar Filing: NYMOX PHARMACEUTICAL CORP - Form SC 13D

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS*
2(D) OR 2(E) []*

6
CITIZENSHIP OR PLACE OF ORGANIZATION*

United States of America

*

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH*

7
SOLE VOTING POWER

2,167,550

8*

SHARED VOTING POWER

-0-*

9
SOLE DISPOSITIVE POWER

2,167,550

10*

SHARED DISPOSITIVE POWER

-0-*

11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,167,550*

12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
(See Instructions)*

X 45,050 shares held in trust for the benefit of the children of Mr. Robinson*

13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

5.66%

*

14
TYPE OF REPORTING PERSON (See Instructions)

IN*
Item 1. Security and Issuer*
Nymox Pharmaceutical Corporation*
Common Stock*

Edgar Filing: NYMOX PHARMACEUTICAL CORP - Form SC 13D

9900 Cavendish Boulevard
St. Laurent, Quebec, Canada
H4M 2V2

Item 2. Identity and Background

- (a) James G. Robinson
- (b) 10 E. Lee Street, Suite 2705 Baltimore, MD 21202
- (c) Chief Executive Officer, Morgan Creek Productions, 10351 Santa Monica Blvd,*
Los Angeles CA, 90025
- (d) N/A
- (e) N/A
- (f) United States of America

Item 3. Source and Amount of Funds or Other Considerations

Personal funds used to acquire \$7,008,412.50 basis in stock
Personal funds used to acquire \$196,470.50 held in trust for James G.*
Robinson's children*

Item 4. Purpose of Transaction

Purpose of transaction is for profit. James G. Robinson has been recently*
elected as a board member effective 07/28/2015.*

Item 5. Interest in Securities of the Issuer

- (a) 2,167,550 shares comprising 5.66% of total common shares outstanding
- (b) 2,167,550 shares
- (c) N/A
- (d) N/A
- (e) N/A

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect*
to Securities of the Issuer N/A

Item 7. Material to Be Filed as Exhibits - N/A

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify*
that the information set forth in this statement is true, complete and correct.*

Dated

/s/

Signature

Name/Title

The original statement shall be signed by each*
person on whose behalf the statement is filed or his authorized representative.*
If the statement is signed on behalf of a person by his authorized*
representative (other than an executive officer or general partner of this*
filing person), evidence of the representative's authority to sign on behalf*
of such person shall be filed with the statement, provided, however, that a*
power of attorney for this purpose which is already on file with the Commission*
may be incorporated by reference. The name and any title of each person who*
signs the statement shall be typed or printed beneath his signature.*
Attention: Intentional misstatements or omissions of fact constitute Federal*
criminal violations (See 18 U.S.C. 1001).*

Page 1

{WLMLAW W0010741.DOC}

{WLMLAW W0010741.DOC}

{WLMLAW W0010741.DOC}

{WLMLAW W0010741.DOC}